INTENT Biologics Receives FDA Breakthrough Therapy Designation for PEP Biologic™ for its Phase 3 Ready Flagship Indication

INTENT Biologics received FDA Breakthrough Therapy Designation for PEP Biologic™ in its Phase 3 ready flagship indication. The designation is a significant regulatory milestone that can accelerate development/priority review pathways. Overall, this is a meaningful positive step for the program’s near-term prospects and investor sentiment.

Analysis

INTENT Biologics received FDA Breakthrough Therapy Designation for PEP Biologic™ in its Phase 3 ready flagship indication. The designation is a significant regulatory milestone that can accelerate development/priority review pathways. Overall, this is a meaningful positive step for the program’s near-term prospects and investor sentiment.